A prospective, multi center, open label phase IV clinical study to evaluate the safety and efficacy of Trifarotene or Aklief 50 microgram per gram cream in subjects with acne vulgaris over 12 weeks. - NIL

开始日期2024-08-26

申办/合作机构

Galderma SA (Switzerland)

[+1]

NCT06733402

/ Completed临床1期

A Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-group Study, Comparing Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A, Inc.) to Aklief® Cream (US REFERENCE LISTED DRUG), Aklief Cream (REFERENCE PRODUCT) and Each Active Treatment to a Placebo Control in the Treatment of Acne Vulgaris.

To demonstrate the efficacy, therapeutic equivalence and safety of Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and US Reference Listed Drug, Canadian Reference Product over the placebo control in the treatment of acne vulgaris.

开始日期2024-06-20

申办/合作机构

Taro Pharmaceuticals U.S.A., Inc.

NCT06063473

/ Completed临床1期

A Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-group Study, Comparing Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A, Inc.) and to AKLIEF® Cream (Trifarotene 0.005%,Galderma) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris

To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris

开始日期2023-02-22

申办/合作机构

Taro Pharmaceuticals U.S.A., Inc.

100 项与曲法罗汀相关的临床结果

登录后查看更多信息

100 项与曲法罗汀相关的转化医学

登录后查看更多信息

100 项与曲法罗汀相关的专利（医药）

登录后查看更多信息

项与曲法罗汀相关的文献（医药）

2025-04-01·INTERNATIONAL JOURNAL OF DERMATOLOGY

One Acne™: A holistic management approach to improve overall skin quality and treatment outcomes in acne with or without sensitive skin

Review

作者: Baldwin, Hilary ; Chavda, Rajeev ; Tan, Jerry ; Lain, Edward (Ted) ; Beleznay, Katie ; Brinkhuizen, Tjinta ; Layton, Alison M. ; Lachmann, Nadège ; Kircik, Leon

Abstract:

Acne and sensitive skin can take a profound toll on patients' well‐being, which can be exacerbated if the conditions are experienced together. This narrative review aims to identify appropriate treatments to facilitate a holistic management approach to acne (One Acne™), sensitive skin, and acne‐induced sequelae and describe the role of treatments in improving skin quality. Topical retinoids are considered the preferred first‐line option for acne treatment by dermatologists, either as monotherapy or in combination with other treatments, because of their ability to target various aspects of the disease. Tretinoin, trifarotene, adapalene, and tazarotene have all been assessed in clinical studies for managing acne‐associated scarring, with varying success, with the latter three reported to improve skin quality. Moreover, some corrective procedures, e.g., injectable non‐animal stabilized hyaluronic acid (NASHA) fillers, have proven effective for treating acne scarring. Both treatment types may complement each other to provide optimal treatment outcomes and patient satisfaction, as observed in several patients receiving concomitant treatment with NASHA fillers/topical trifarotene. Adjunctive use of cleansers, moisturizers, and photoprotection‐containing ingredients such as vitamin B3, glycerin, or pro‐vitamin B3 may also complement drug/corrective treatments to reduce skin irritation and risk of scarring, as well as improve skin hydration, tone, and overall appearance. This narrative review highlights that comprehensive skincare regimens should be used throughout acne patients' journeys to reduce treatment‐related irritation, improve treatment outcomes, adherence, and satisfaction, and enhance overall skin quality. Patients with sensitive skin should choose tailored skincare products to maintain skin barrier integrity and restore skin function.

2025-03-01·Dermatology and Therapy

Recommendations to Improve Outcomes in Acne and Acne Sequelae: A Focus on Trifarotene and Other Retinoids

Letter

作者: Noor, Omar ; Hamzavi, Iltefat ; Hebert, Adelaide ; Lain, Edward ; Kircik, Leon ; Moore, Angela ; Issa, Naiem ; Kwong, Pearl ; Woolery-Lloyd, Heather ; Schlesinger, Todd ; Weiss, Jonathan ; York, J P ; Alexis, Andrew ; Holcomb, Kate Zibilich ; Baldwin, Hilary ; Chavda, Rajeev

Acne vulgaris affects nearly 50 million people in the USA, ranking as the eighth most prevalent disease globally. This chronic inflammatory skin condition often results in sequelae, including atrophic acne scars, acne-induced macular erythema and acne-induced hyperpigmentation, impacting patients' quality of life. This commentary article reviews the use of topical retinoids, with a particular emphasis on trifarotene cream 0.005%, for managing both acne and acne sequelae. Topical retinoids are considered central to improving treatment outcomes because of their established efficacy, safety and tolerability. Adapalene, tretinoin and tazarotene have demonstrated efficacy in reducing acne and acne sequelae in several studies. Trifarotene has been extensively studied in Phase 3 trials, demonstrating notable success in treating mild-to-moderate acne. Recently, two large-scale, randomized, blinded, Phase 4 clinical trials investigated trifarotene cream 0.005% in patients with atrophic acne scarring and acne-induced hyperpigmentation across all Fitzpatrick phototypes. The START study found that there was a greater reduction in total atrophic acne scar count in the trifarotene group compared with the vehicle group at Week 24 (55.2% vs 29.9%) with statistical significance established as early as Week 2 (P = 0.001). Based on this evidence, we recommend that topical retinoids should be introduced as first-line therapy for the treatment of acne and acne sequelae. Retinoids should be implemented into a treatment routine as early as possible, especially for patients with darker Fitzpatrick phototypes or patients at risk of atrophic acne scarring. Furthermore, retinoids should be incorporated within a comprehensive skincare regimen that includes adequate photoprotection when treating patients with darker Fitzpatrick phototypes. Finally, management of acne and acne sequelae should include maintenance therapy with topical retinoids. This article supports the American Academy of Dermatology's call for acne sequelae treatment guidance and emphasizes the need for continued research to optimize patient care.

2025-02-01·Dermatology and Therapy

A Real-World Approach to Trifarotene Treatment in Patients with Acne and Acne Sequelae Based on the Experience of the Italian Acne Board

Letter

作者: Dall'Oglio, Federica ; Tretti Clementoni, Matteo ; Barbareschi, Mauro ; Annunziata, Maria Carmela ; Skroza, Nevena ; Monfrecola, Giuseppe ; Bettoli, Vincenzo ; Micali, Giuseppe ; Veraldi, Stefano

Acne and acne sequelae can have an important impact on patients' quality of life, affecting interpersonal relationships and social functioning. Acne-induced scars (AIS) and acne-induced macular hyperpigmentation (AIH), in particular, are a major concern for patients with acne, as their management is challenging and often unsatisfactory. Retinoids are considered the mainstay of acne treatment because of their action on multiple pathogenetic factors, and there is increasing evidence that they can also improve AIS and AIH. Trifarotene, a topical retinoid with selectivity for retinoic acid receptor (RAR)-γ, has undergone an extensive clinical development programme, demonstrating its efficacy in treating facial and truncal acne and improving acne sequelae. In this article, we review the main evidence supporting the use of trifarotene in patients with acne and acne sequelae and provide place-in-therapy suggestions based on the experience of the Italian Acne Board with this drug in real-life practice. Trifarotene can be used successfully, as monotherapy or in association with other treatments, in most clinical settings of acne, but it plays an essential role in patients with existing AIS and AIH, those with a clinical or personal history of scarring and those who are predisposed to AIH. Owing to its long-term efficacy and tolerability, trifarotene is also a good option as a maintenance treatment. As with other topical retinoids, patients undergoing trifarotene therapy should be given advice on how to minimise local irritation when starting treatment.

项与曲法罗汀相关的新闻（医药）

2025-06-05

·galderma.com

International Congress of Dermatology 2025: Galderma’s Scientific Presentations

Galderma will present data from across its Therapeutic Dermatology portfolio at the XIV International Congress of Dermatology (ICD), taking place in Rome, Italy, on June 18-21, 2025, including updates on its investigations in acne, non-melanoma skin cancer, and prurigo nodularis. First author Abstract title Presentation type S. Ständer Nemolizumab long-term efficacy and safety up to 100 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis: An interim analysis Late-breaking abstract Presented Saturday, June 21, 2025, at 08:30 – 08:35 AM CET Orange room R. Szeimies Personalizing Actinic Keratosis Treatment for Immunocompromised Patients (IM-PAKT): Patient scenarios E-poster #1673 R. Szeimies Artificial daylight photodynamic therapy with methyl aminolevulinate (ArtLight): A real-world study E-poster #1675 A. Moore Quantifying pigmentation: A colorimetric analysis assessing the impact of trifarotene on acne-induced hyperpigmentation (AIH) E-poster #1680 M. Schaller Recommendations for long-term rosacea management from The Rosacea — Expert Advice on Combined and Holistic approaches (REACH) group’s Global Scientific Committee E-poster #1677 First author Abstract title Presentation type S. Ständer Nemolizumab long-term efficacy and safety up to 100 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis: An interim analysis Late-breaking abstract Presented Saturday, June 21, 2025, at 08:30 – 08:35 AM CET Orange room R. Szeimies Personalizing Actinic Keratosis Treatment for Immunocompromised Patients (IM-PAKT): Patient scenarios E-poster #1673 R. Szeimies Artificial daylight photodynamic therapy with methyl aminolevulinate (ArtLight): A real-world study E-poster #1675 A. Moore Quantifying pigmentation: A colorimetric analysis assessing the impact of trifarotene on acne-induced hyperpigmentation (AIH) E-poster #1680 M. Schaller Recommendations for long-term rosacea management from The Rosacea — Expert Advice on Combined and Holistic approaches (REACH) group’s Global Scientific Committee E-poster #1677 Galderma will also host a symposium at ICD, exploring the latest advances in addressing itch and lesion control in both prurigo nodularis and atopic dermatitis. Further details can be found here and below. Speakers Symposium title Details Prof. Sarina Elmariah Dr. Brian Kim Prof. Martin Metz Dr. Andrew Pink Ditching the Itch: Latest Advances in Itch Relief and Long-Term Lesion Control for Atopic Dermatitis and Prurigo Nodularis Friday, June 20 12:30 – 1:30 PM CET Green Room Speakers Symposium title Details Prof. Sarina Elmariah Dr. Brian Kim Prof. Martin Metz Dr. Andrew Pink Ditching the Itch: Latest Advances in Itch Relief and Long-Term Lesion Control for Atopic Dermatitis and Prurigo Nodularis Friday, June 20 12:30 – 1:30 PM CET Green Room

2024-10-25

·PRNewswire

Sun Pharma Announces Multiple Data Presentations Highlighting its Dermatology Portfolio to be Featured at the 2024 Fall Clinical Dermatology Conference

Data from a wide range of the Sun Pharma dermatology portfolio, including data on alopecia areata, psoriasis, acne and actinic keratosis products, will be highlighted during the meeting. MUMBAI, India and PRINCETON, N.J., Oct. 25, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced it will present more than a dozen posters at the 44th Annual Fall Clinical Dermatology Conference, being held October 24-27, 2024, in Las Vegas, Nevada. The presentations will include data from across the Sun Pharma dermatology portfolio, including study results for LEQSELVI™ (deuruxolitinib), WINLEVI® (clascoterone), ILUMYA® (tildrakizumab-asmn), ODOMZO® (sonidegib) and LEVULAN® KERASTICK® (aminolevulinic acid HCl) + BLU-U® (blue light photodynamic therapy). "As an organization dedicated to supporting the dermatology community, the Fall Clinical Dermatology Conference offers a vitally important forum to present new data and highlight how Sun's innovative dermatology portfolio can support those living with alopecia areata, psoriasis, acne and other skin-related diseases," said Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Development at Sun Pharma. "We look forward to sharing data from across our portfolio with the dermatology research community and our esteemed industry colleagues." Six abstracts, accepted for poster presentations, will highlight clinical efficacy and safety data of LEQSELVI™ (deuruxolitinib). Approved earlier this year by the U.S. Food and Drug Administration for the treatment of adults with severe alopecia areata, LEQSELVI™ is an oral JAK inhibitor that interrupts the pathways thought to contribute to hair loss in severe AA and delivered statistically significant efficacy at 24 weeks across two Phase 3 clinical trials. LEQSELVI™ data being presented at Fall Clinical showcase pooled long-term results for ongoing clinically meaningful improvements in scalp hair regrowth in adults with alopecia areata. Additionally, two posters will present patient and clinician preferences for the treatment of alopecia areata. The WINLEVI® poster presentations will include new data showing significant reductions in casual facial sebum levels from baseline, stability in the presence of other commonly prescribed acne medications, and efficacy and safety from a pilot study in patients with skin of color. The conference will also feature data from three additional WINLEVI® studies. Sun Pharma will present the following posters at the 2024 Fall Clinical Dermatology Conference: LEQSELVI™ Presentations: Deuruxolitinib results in ongoing clinically meaningful improvements in scalp hair regrowth in adults with alopecia areata: Pooled long-term efficacy and safety data from the open-label extension studies Patient Preferences for the Treatment of Alopecia Areata A Discrete Choice Experiment to Assess Clinician Preferences for the Treatment of Alopecia Optimization of deuruxolitinib dosing in adult patients with alopecia area: Results from a randomized, parallel-group, multicenter Phase 2 trial Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials Improvement in anxiety and depression in adult patients with severe alopecia areata treated with deuruxolitinib: Pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials WINLEVI® Presentations: Clinical evaluation of the sebum reduction induced by clascoterone cream 1%: Week 12 interim analysis Assessment of clascoterone cream 1% levels when layered with other topical acne medications Efficacy and safety of clascoterone cream 1% in patients with acne with skin of color: 16-week interim analysis The efficacy and safety of clascoterone cream 1% for the treatment of acne vulgaris are not dependent on patient age and sex: Results of a post hoc analysis Improvement in skin moisturization and lack of barrier damage with clascoterone cream 1% treatment: Results of a randomized, single-blind, split-face study in acne-prone individuals Comparison of the efficacy of clascoterone vs trifarotene and tazarotene for the treatment of acne vulgaris at Week 12: A systematic review and meta-analysis ILUMYA® Presentation: A systematic literature review and meta-analysis of the real-world effectiveness, quality of life, and safety of tildrakizumab for moderate-to-severe plaque psoriasis ODOMZO® Presentation: Lower rate of discontinuation of sonidegib compared to vismodegib in a real-world analysis of patients with basal cell carcinoma LEVULAN® KERASTICK® + BLU-U® Presentation: Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by blue light in the treatment of facial cutaneous squamous cell carcinoma in situ About Sun Pharmaceutical Industries Limited. (CIN – L24230GJ1993PLC019050) Sun Pharma is the world's leading specialty generics company with a presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. For further information, please visit and follow us on LinkedIn & X (Formerly Twitter). Disclaimer: Statements in this "document" describing Sun Pharma's objectives, projections, estimates, expectations, plans or predictions, industry conditions, or events may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. Sun Pharma does not undertake any obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. SOURCE Sun Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期临床结果临床2期

2024-09-06

·凯莱英药闻

本周国内创新药IND和NDA，全球新药III期临床汇总

欢迎关注凯莱英药闻（收集周期：9.2-9.6，国内部分为首次申请临床、首次申请上市的创新药）国内创新药IND汇总 1、和誉生物：ABSK043片作用机制：PD-L1小分子抑制剂适应症：肿瘤 9月4日，和誉生物的ABSK043片的临床试验申请（IND）获CDE受理。ABSK043是和誉生物独立自主研发的口服PD-L1小分子抑制剂，是国内首个、全球第二个发布疗效数据的口服PD-L1小分子。与抗体相比，小分子的免疫原性风险低，剂量调节更便捷，患者口服可减少因静脉输注而产生的医疗住院负担。基于小分子的优势和良好的安全性以及初步疗效结果，ABSK043有望成为Best-in-class，为更多肿瘤患者带来临床获益。根据在2023 ESCO公布的数据：在针对多种晚期实体瘤的临床一期爬坡试验中，ABSK043在11例疗效可评估的BID给药患者中的ORR高达27.3%，且所有剂量组均未发生剂量限制性毒性事件或发现周围神经病变事件。 2、阿斯利康/诚益生物：AZD5004薄膜包衣片作用机制：GLP-1RA 激动剂适应症：减肥、降糖 9月4日，阿斯利康/诚益生物开发的AZD5004薄膜包衣片的IND获CDE受理。AZD5004 (ECC5004) 是一种口服GLP-1RA 激动剂，用于治疗肥胖症、2 型糖尿病和其他心脏代谢疾病。该药物既可以作为单药治疗，也可以与针对肠道激素胰淀素的抗肥胖药物AZD6234联合使用。2023年11月，阿斯利康与诚益生物签署了一项独家许可协议，合作开发GLP-1药物ECC5004。在美国开展的1期临床试验显示，与安慰剂相比，在10 mg与30 mg剂量下，药物展现积极的减重与血糖降低效果，且具有>70%的口服生物利用度以及良好的耐受性。 3、阿斯利康：AZD8630吸入剂作用机制：TSLP单抗适应症：哮喘 9月4日，阿斯利康的AZD8630吸入剂的IND获CDE受理。AZD8630（AMG 104）是一款抗胸腺基质淋巴细胞生成素(TSLP) 单克隆抗体，有望实现每日一次吸入。TSLP是一种主要由气道上皮表达的细胞因子，在环境损伤时释放，引发一系列下游炎症过程。有充分证据表明，它能够分化2型细胞中幼稚的CD4+T淋巴细胞，产生IL-4、IL-5、IL-13，并降低与1型细胞相关的γ干扰素（IFN-γ）的表达，对多种细胞产生影响。文献表明TSLP信号异常与其他炎症性变态反应性疾病密切相关，包括特应性皮炎、嗜酸性食管炎、慢性阻塞性肺疾病和特发性肺纤维化。此外，它的表达也被病毒、细菌和寄生虫病原体的感染所触发。 I期试验显示，AZD8630每日一次给药，在评估的剂量下长达 28 天内给药是安全的且耐受性良好。接受高剂量 AZD8630治疗的患者 FeNO 显著降低（与安慰剂相比降低 23%， p =0.037）；这种降低从 7 天开始明显，持续到治疗期结束（28 天）。大多数不良事件是轻微的，A 部分或 B 部分均未发生严重不良事件。PK 在健康和哮喘受试者中呈线性且一致，支持每日一次给药。 4、科伦博泰：SKB571 作用机制：—— 适应症：肿瘤 9月5日，科伦博泰的注射用SKB571的IND获CDE受理。SKB571是一款创新双抗ADC，目前处于临床前的开发阶段，具体靶点尚不明确；主要针对肺癌、消化道肿瘤等多种实体瘤。该药物通过科学的靶点组合选择和差异化的双抗分子设计，提升对肿瘤的靶向性，并有利于克服肿瘤异质性，提升疗效；通过搭配OptiDCTM平台的高亲水性毒素-连接子策略，不仅DAR值均一，且展现了良好的体内药代动力学性质。临床前研究显示，该产品在多种人源肿瘤异种移植（PDX）模型和食蟹猴中，分别展现了良好的抗肿瘤效果及安全性。 2024年8月，科伦博泰宣布与默沙东将就SKB571项目行使独家选择权；默沙东向科伦博泰支付3,750万美元，且待达致特定开发及销售里程碑后，向科伦博泰支付进一步里程碑付款，以及商业化分级特许权使用费等。 5、Galderma：曲法罗汀乳膏作用机制：RARγ激动剂适应症：痤疮 9月5日，Galderma的曲法罗汀乳膏的IND获CDE受理。曲法罗汀（Trifarotene）是新一代维A酸类药物，被FDA批准用于治疗面部和躯干痤疮。该药物高选择作用于视黄酸受体γ(RAR-γ) ，RAR-γ是皮肤中主要的RAR亚型；当曲法罗汀选择性发挥疗效的同时，减少了对其他RAR亚型的影响，有效降低了靶器官副作用和皮肤刺激，能以更低的浓度达到同样的治疗效果。大规模 III 期研究PERFECT 1和PERFECT 2 证明，曲法罗汀最早在使用第1周即可有效减少面部病变。Satisfy研究结果显示，从第12周到第52周，曲法罗汀使面部IGA改善由26.6%增加到65.1%，躯干PGA改善从38.6%增加到66.9%。整体成功率57.9%。国内创新药NDA汇总 1、步长生物：注射用艾帕依泊汀α 作用机制：EPO-Fc融合蛋白适应症：贫血 9月3日，步长生物的注射用艾帕依泊汀α的上市申请获CDE受理。艾帕依泊汀α是一款促红细胞生成素-Fc（EPO-Fc）融合蛋白，采用的是Fc蛋白融合技术，属于长效红细胞生成素（EPO）药物。根据《中国肾性贫血诊治临床实践指南2021》，治疗肾性贫血的药物共有4 种，分为一代、二代和三代EPO，一代为短效EPO，二代和三代均为长效EPO。一代短效EPO 总体的市场规模保持相对稳定，二代长效EPO 2020 年首次国内上市后，市场规模尚未打开，但在2023 年年初被首次纳入医保，预计有望提升市场规模，三代超长效EPO 2018 年国内获批上市，但一直未在国内启动商业化。公司开展了一项多中心、随机、开放、阳性药对照的 III 期临床研究，旨在施行血液透析的中国慢性肾脏病贫血患者中，比较艾帕依泊汀α和重组 EPO 阿法依泊汀用于维持治疗的有效性和安全性。该试验已经于 2023 年 4 月完成试验，但是试验结果尚未公布。 2、诺和诺德：帕西生长素注射液作用机制：GH类似物适应症：生长激素缺乏症 9月5日，诺和诺德的帕西生长素注射液的上市申请获CDE受理。帕西生长素（Somapacitan）为每周一次的长效生长激素，2020年获FDA批准用于治疗成人生长激素缺乏症，商品名为Sogroya；2023年4月将适应症扩大到2.5岁及以上儿童人群。在一项多中心、开放标签、阳性对照、平行组3期REAL4试验中，每周一次接受somapacitan治疗的患者年化生长高度为11.2cm/年。此外，该药物在儿童身高年化生长速度上非劣效于norditropin，未来可与norditropin形成产品组合，满足各类不同患者的需求。目前在美国，Sogroya的10mg/1.5ml规格售价为2496美金(约合1.77万元)。全球新药III期临床汇总感谢关注、转发，转载授权、加行业交流群，请加管理员微信号“hxsjjf1618”。 “在看”点一下

临床申请临床2期临床1期申请上市临床结果

100 项与曲法罗汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11225	曲法罗汀	D10AD06	DB12808

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
寻常痤疮	美国	Galderma Laboratories LP	2019-10-04

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
常染色体隐性鱼鳞病	临床2期	美国	Mayne Pharma International Pty Ltd.	2019-05-01
常染色体隐性鱼鳞病	临床2期	澳大利亚	Mayne Pharma International Pty Ltd.	2019-05-01
常染色体隐性鱼鳞病	临床2期	加拿大	Mayne Pharma International Pty Ltd.	2019-05-01
常染色体隐性鱼鳞病	临床2期	法国	Mayne Pharma International Pty Ltd.	2019-05-01
常染色体隐性鱼鳞病	临床2期	德国	Mayne Pharma International Pty Ltd.	2019-05-01
常染色体隐性鱼鳞病	临床2期	以色列	Mayne Pharma International Pty Ltd.	2019-05-01
常染色体隐性鱼鳞病	临床2期	西班牙	Mayne Pharma International Pty Ltd.	2019-05-01
常染色体隐性鱼鳞病	临床2期	乌克兰	Mayne Pharma International Pty Ltd.	2019-05-01
常染色体隐性鱼鳞病	临床2期	英国	Mayne Pharma International Pty Ltd.	2019-05-01
板层状鳞癣	临床2期	美国	Mayne Pharma International Pty Ltd.	2019-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05550337 (CTgov)	临床3期	寻常痤疮	807	Trifarotene 0.005 % Topical Cream (Test: Trifarotene Cream, 0.005%)	齋範餘廠鏇醖壓蓋鹹蓋(窪鑰簾鬱襯餘簾淵網鹹) = 鏇繭獵積憲蓋願餘齋積齋簾衊艱憲窪廠製網窪 (網選窪積壓積鹽簾獵遞, 33.364) 更多	-	2024-09-26
				AKLIEF® (AKLIEF®)	齋範餘廠鏇醖壓蓋鹹蓋(窪鑰簾鬱襯餘簾淵網鹹) = 艱觸顧夢簾夢壓鏇觸憲齋簾衊艱憲窪廠製網窪 (網選窪積壓積鹽簾獵遞, 23.547) 更多
NCT05089708 (LEAP, CTgov)	临床4期	色素沉着过多 \| 寻常痤疮	123	Trifarotene Vehicle Cream	範艱觸製鏇糧築繭齋鏇(齋構淵製積鹹鏇鹽願夢) = 廠願網構艱鑰蓋遞簾構齋網願構艱願網醖齋鹹 (糧觸壓獵衊築齋醖壓鑰, 0.24) 更多	-	2023-12-20
NCT04856904 (Phase 4 Controlled Study, Pubmed \| Dermatol Ther (Heidelb))	临床4期	萎缩性痤疮瘢痕	121	Trifarotene 50 μg/g	蓋鏇顧鑰積製繭蓋憲網(製範膚餘鬱製餘壓網窪) = The incidence of treatment-emergent adverse events was 5.8% (trifarotene) and 2.5% (vehicle); most common (> 1%) was skin tightness (1.7% vs 0.8%), and all events were mild to moderate in severity 獵蓋淵範鬱鹽窪艱憲艱 (壓艱襯網鹽遞顧簾壓願 )	积极	2023-12-01
				Vehicle
NCT05089708 (LEAP, EADV2023)	临床4期	色素沉着过多	-	Trifarotene 50µg/g cream	積壓願夢築艱遞衊鏇觸(選齋齋壓鬱憲網範範醖) = 齋鑰願鬱膚積鑰願獵廠窪醖構築網艱憲繭繭繭 (廠壓獵製鑰繭鑰艱顧醖 ) 更多	积极	2023-10-11
				Vehicle cream	積壓願夢築艱遞衊鏇觸(選齋齋壓鬱憲網範範醖) = 獵衊網選願鬱鏇顧選築窪醖構築網艱憲繭繭繭 (廠壓獵製鑰繭鑰艱顧醖 ) 更多
The DUAL study (WCD2023)	N/A	严重痤疮	202	Trifarotene 50 μg/g cream + oral doxycycline 120 mg	鏇夢鑰觸醖衊鹽壓繭艱(鏇範簾鹽憲鑰製窪繭獵) = 築衊憲築觸壓構襯窪鹽獵壓願膚窪鏇醖鏇夢製 (製襯選鑰鹹獵憲鹹鏇憲 )	积极	2023-07-04
				Trifarotene vehicle + doxycycline placebo	鏇夢鑰觸醖衊鹽壓繭艱(鏇範簾鹽憲鑰製窪繭獵) = 膚顧壓襯鏇膚願壓選範獵壓願膚窪鏇醖鏇夢製 (製襯選鑰鹹獵憲鹹鏇憲 )
WCD2023	临床3期	-	-	Trifarotene 0.005% cream	鬱夢顧鑰鹽糧觸顧窪鏇(範獵鬱蓋餘鏇蓋衊築糧) = 膚遞鏇襯艱糧蓋壓網積願齋餘蓋廠獵鑰觸製廠 (遞繭鬱網糧繭觸壓鏇蓋 )	积极	2023-07-03
				Vehicle	鬱夢顧鑰鹽糧觸顧窪鏇(範獵鬱蓋餘鏇蓋衊築糧) = 餘糧鹽鑰簾顧壓憲餘簾願齋餘蓋廠獵鑰觸製廠 (遞繭鬱網糧繭觸壓鏇蓋 )
WCD2023	临床4期	严重痤疮	198	Combination therapy	蓋憲築夢憲醖衊糧衊艱(淵鹹鏇糧膚蓋憲淵築遞) = 鬱鏇醖艱願製齋遞衊範鬱淵膚壓襯獵鬱獵簾網 (鏇衊鹹網觸遞獵選鹽積 ) 更多	-	2023-07-03
AAD2023	临床3期	-	-	Trifarotene 0.005% cream	構鹹夢窪觸衊鏇鬱製網(鏇鏇鏇艱選鬱齋壓鏇鏇) = AEs occurred in 28.3% trifarotene group vs 23.5% vehicle-treated and rarely led to study discontinuation (1.9% trifarotene, 0.2% vehicle) 繭網窪遞壓遞選願築築 (鬱糧鬱鹽鑰繭廠構憲襯 ) 更多	积极	2023-03-17
				Vehicle
EADV2022	临床3期	寻常痤疮	-	Trifarotene cream	餘餘窪醖獵鏇範壓廠簾(獵積壓窪餘醖衊繭製糧) = 憲淵蓋膚廠範鏇蓋淵製醖選簾鏇鑰獵選製糧襯 (選鏇憲選遞鑰壓願顧鏇 ) 更多	积极	2022-09-07
				Vehicle	餘餘窪醖獵鏇範壓廠簾(獵積壓窪餘醖衊繭製糧) = 構齋觸齋積淵膚積繭壓醖選簾鏇鑰獵選製糧襯 (選鏇憲選遞鑰壓願顧鏇 ) 更多
NCT04451330 (DUAL, CTgov)	临床4期	寻常痤疮	202	Doxycycline Placebo+Trifarotene Vehicle	範築鑰築簾醖繭選淵鹹(構壓鬱淵糧蓋繭繭齋醖) = 糧選襯鬱艱蓋淵鑰繭齋憲鏇獵襯鹽觸夢鑰蓋願 (壓顧網糧餘遞窪築廠醖, 3.14) 更多	-	2022-05-10